NCT00609804 - Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

November 30, 2014

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Sorafenib

Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.

DRUG

Erlotinib

Erlotinib 150 mg once daily by mouth

Trial Locations (16)

20817

Center for Cancer and Blood Disorders, Bethesda

National Capital Clinical Research Consortium, Bethesda

30060

Wellstar Cancer Research, Marietta

30501

Northeast Georgia Medical Center, Gainesville

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Associates in Hematology Oncology, Chattanooga

Chattanooga Oncology Hematology Associates, Chattanooga

39202

Jackson Oncology Associates, Jackson

40207

Norton Cancer Institute, Louisville

47802

Providence Medical Group, Terre Haute

63017

St. Louis Cancer Care, Chesterfield

64132

Research Medical Center, Kansas City

68114

Nebraska Methodist Cancer Center, Omaha

70806

Hematology Oncology Clinic, LLP, Baton Rouge

07960

Hematology-Oncology Associates of Northern NJ, Morristown